Management of neuroendocrine neoplasms: conformity with guidelines in and outside a center of excellence.
ENETS center of excellence
conformity to clinical guidelines
diagnostic management
neuroendocrine neoplasm
Journal
Endocrine connections
ISSN: 2049-3614
Titre abrégé: Endocr Connect
Pays: England
ID NLM: 101598413
Informations de publication
Date de publication:
15 Jun 2022
15 Jun 2022
Historique:
received:
11
04
2022
accepted:
27
04
2022
pubmed:
7
5
2022
medline:
7
5
2022
entrez:
6
5
2022
Statut:
epublish
Résumé
To improve neuroendocrine neoplasm (NEN) management, the European Neuroendocrine Tumor Society (ENETS) recognised 62 Centers of Excellence (CoE). This retrospective study compares conformity of patients' initial management within vs outside an ENETS CoE with clinical practice guidelines (CPGs). Patients diagnosed with a NEN between August 2018 and July 2020 and presented in the Lyon-CoE Multidisciplinary Tumour Board (MDT) were included. Factors potentially associated with the conformity of initial management (work-up and first treatment) to CPG underwent univariate and multivariate analyses. Among the 615 included patients, 170 (27.6%) were initially managed in the CoE and 445 (72.4%) were only presented at the CoE-MDT. Patients in the CoE group more often had intestinal or pancreatic primaries, metastatic disease (61.8% vs 33%), hereditary syndrome, and a functioning tumour. Work-up conformity was 37.1% in the CoE (vs 29.9%, P = 0.09); this was 95.8% for the first treatment (vs 88.7%, P = 0.01). After multivariate analysis, CPG conformity was significantly higher for patients managed in the CoE, for younger patients, for those having a grade 1-2 tumour, and a genetic syndrome. Pancreatic and small intestinal (SI) NET surgeries performed in the CoE had a higher splenic preservation rate during left pancreatectomy, better detection of multiple tumours in SI surgeries, and higher number of resected lymph nodes. Given the widespread observance of CPG, not all patients require management in the CoE. Referral should be considered for more complex cases such as metastatic diseases, G2 tumours, or carcinoid syndromes. Finally, we should encourage the centralization of NET surgery.
Identifiants
pubmed: 35521801
doi: 10.1530/EC-22-0097
pii: EC-22-0097
pmc: PMC9254288
doi:
pii:
Types de publication
Journal Article
Langues
eng
Références
Endocrine. 2013 Oct;44(2):504-9
pubmed: 23471696
Neuroendocrinology. 2018;106(4):357-365
pubmed: 29320780
Ann Oncol. 2020 Jul;31(7):844-860
pubmed: 32272208
J Clin Med. 2019 Jun 25;8(6):
pubmed: 31242670
BMC Cancer. 2021 Feb 9;21(1):146
pubmed: 33563241
Cancer. 2015 Feb 15;121(4):589-97
pubmed: 25312765
Neuroendocrinology. 2016;103(2):186-94
pubmed: 26731334
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
Neuroendocrinology. 2021;111(1-2):129-138
pubmed: 32040951
Dig Liver Dis. 2020 May;52(5):473-492
pubmed: 32234416
J Clin Med. 2019 Sep 12;8(9):
pubmed: 31547431
Pancreas. 2017 Jul;46(6):715-731
pubmed: 28609357
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
Eur J Cancer. 2016 May;58:90-6
pubmed: 26974708
Ann Oncol. 2013 Jan;24(1):152-60
pubmed: 22967994
World J Surg. 2013 Jul;37(7):1695-700
pubmed: 23657749
Oncologist. 2019 Aug;24(8):e775-e783
pubmed: 31073021
J Oncol Pract. 2010 Nov;6(6):e11-6
pubmed: 21358944
Ann Oncol. 2019 Jul 1;30(7):1143-1153
pubmed: 31081028
Ann Oncol. 2017 Nov 01;28(11):2852-2859
pubmed: 29117335
Ann Oncol. 2004 Feb;15(2):307-15
pubmed: 14760127
Curr Opin Endocrinol Diabetes Obes. 2012 Aug;19(4):306-13
pubmed: 22760514